Skip to content

Study · Randomized controlled trial · n = 10 · 2022

4 results

Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.

Nielsen CK, Øhrstrøm CC, Kielgast UL, Hansen DL, Hartmann B, Holst JJ, Lund A, Vilsbøll T, Knop FK

Diabetes care1 Jun 2022Cited by 13 (Europe PMC)

PMID35320361 (opens in a new tab)DOI10.2337/dc21-2252 (opens in a new tab)PepBankPUB-35320361
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants with postbariatric hypoglycemia, dasiglucagon raised nadir plasma glucose to 3.9 ± 0.3 mmol/L versus 3.0 ± 0.2 with placebo, P = 0.002.

    In plain wordsIn participants with postbariatric hypoglycemia, 80 μg dasiglucagon raised the lowest blood glucose compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseNadir plasma glucose
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    80 μg · subcutaneous · Single doseAs given in this study (human).

    Measurements

    Nadir plasma glucose
    3.9 mmol/L
    80 μg dasiglucagon, SEM 0.3
    Nadir plasma glucose
    3 mmol/L
    placebo, SEM 0.2

    Source sentences

    Summary
    Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.…
    1 context sentence
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with postbariatric hypoglycemia, dasiglucagon raised nadir plasma glucose to 4.5 ± 0.2 mmol/L versus 3.0 ± 0.2 with placebo, P = 0.0002.

    In plain wordsIn participants with postbariatric hypoglycemia, 200 μg dasiglucagon raised the lowest blood glucose compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseNadir plasma glucose
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    200 μg · subcutaneous · Single doseAs given in this study (human).

    Measurements

    Nadir plasma glucose
    4.5 mmol/L
    200 μg dasiglucagon, SEM 0.2
    Nadir plasma glucose
    3 mmol/L
    placebo, SEM 0.2

    Source sentences

    Summary
    Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.…
    1 context sentence
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants with postbariatric hypoglycemia, 80 μg dasiglucagon reduced time in hypoglycemia by 70.0 min versus placebo, P = 0.030.

    In plain wordsIn participants with postbariatric hypoglycemia, 80 μg dasiglucagon reduced time in hypoglycemia by 70.0 minutes compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime in hypoglycemia
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    80 μg · subcutaneous · Single doseAs given in this study (human).

    Measurements

    Time reduction
    70 min
    80 μg versus placebo

    Source sentences

    Summary
    Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.…
    1 context sentence
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In participants with postbariatric hypoglycemia, 200 μg dasiglucagon reduced time in hypoglycemia by 70.0 min versus placebo, P = 0.008.

    In plain wordsIn participants with postbariatric hypoglycemia, 200 μg dasiglucagon reduced time in hypoglycemia by 70.0 minutes compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime in hypoglycemia
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    200 μg · subcutaneous · Single doseAs given in this study (human).

    Measurements

    Time reduction
    70 min
    200 μg versus placebo

    Source sentences

    Summary
    Compared with placebo, treatment with both 80 and 200 μg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 μg dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 μg dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.…
    1 context sentence
    Summary · context
    In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring-verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT03984370

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

University Hospital, Gentofte, Copenhagenn = 1018 Sept 2019 to 26 Feb 2020

Hyperinsulinemic Hypoglycemia · Postprandial Hypoglycemia

Trial pageClinicalTrials.govUpdated 31 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.